The Effect of Semaglutide on the Intestinal Flora in Obesity

NCT07323134•Beijing Chao Yang Hospital

Summary

For obese individuals, semaglutide treatment was adopted. By using multi-omics techniques such as fecal metagenomic sequencing and based on in vitro strain screening platforms, the effects and specific mechanisms of semaglutide on the intestinal flora of obese patients were clarified.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•18 to 60 years old;
•BMI ≥ 30kg/m²;
•At least one self-reported history of unsuccessful lifestyle weight loss;
•Subjects who agree to participate in the project and sign the informed consent form.

Exclusion Criteria

•Weight changes within 3 months prior to screening (self-reported) \>5%;
•Having received any drug treatment for obesity within the three months prior to screening;
•The application of hypoglycemic drugs within 3 months before screening, or HbA1c≥ 6.5%, or a history of type 1 or type 2 diabetes;
•Participants who have received treatment with immunosuppressants, steroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering drugs and/or other gastrointestinal motility drugs within 3 months prior to screening;
•Previously diagnosed overweight or obesity due to endocrine causes, such as Cushing's syndrome, etc;
•Triglycerides ≥500mg/dL (5.65mmol/L) during screening;
•It is known that there are clinically significant gastric emptying abnormalities (e.g., severe diabetic gastroparesis or gastric outlet obstruction), a history of gastrointestinal diseases and surgical history;
•Abnormal thyroid function;
•History of mental illness;
•History of multiple endocrine tumors or medullary thyroid cancer, family history, or calcitonin ≥6pg/mL;
+6 more criteria

Key Dates

Start Date

February 1, 2026

Primary Completion Date

August 1, 2026

Completion Date

August 1, 2026

Last Updated

January 7, 2026

Enrollment

ESTIMATED participants

Conditions

Obesity

Interventions

Semaglutide Injection

DRUG

Contacts

Jia Liu

CONTACT

13810662843 liujiacy@ccmu.edu.cn

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

RECRUITINGNA

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 7, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effect of Semaglutide on the Intestinal Flora in Obesity

Inclusion Criteria

Exclusion Criteria

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Protein Supplementation Intervention on Body Weight

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss